{"product_id":"isrg-business-model-canvas","title":"Intuitive Surgical, Inc. (ISRG): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a practical, research-based view of how Intuitive Surgical, Inc. creates value through hospital and ambulatory surgery center sales, surgeon training, regulatory partnerships, and recurring income from instruments, accessories, service contracts, and procedure-driven revenue. You'll see the key drivers behind the business, including its majority-owned Fosun JV in China, international distribution in Italy and Spain, \u003cstrong\u003e15-use\u003c\/strong\u003e instruments, high R\u0026amp;D and manufacturing costs, and strategic assets such as its global installed base, intellectual property, AI tools, and large cash reserves.\u003c\/p\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical, Inc. depends on \u003cstrong\u003e5\u003c\/strong\u003e partnership blocks: the China Fosun joint venture, hospitals and ambulatory surgery centers, surgeon training and education partners, regulatory and reimbursement authorities, and distribution partners in Italy and Spain. These links shape market access, adoption, and payment across the company's robotic surgery business.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner block\u003c\/th\u003e\n\u003cth\u003eNumeric anchor\u003c\/th\u003e\n\u003cth\u003eReal-life counterpart\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina Fosun joint venture\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e majority-owned JV\u003c\/td\u003e\n\u003ctd\u003eFosun\u003c\/td\u003e\n\u003ctd\u003eLocal China commercialization, registration, and support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and ambulatory surgery centers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e care settings\u003c\/td\u003e\n\u003ctd\u003eHospitals; ambulatory surgery centers\u003c\/td\u003e\n\u003ctd\u003eSystem placements, procedure volume, recurring instruments, accessories, and service\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon training and education partners\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e adoption layers\u003c\/td\u003e\n\u003ctd\u003eSimulation; proctoring; credentialing\u003c\/td\u003e\n\u003ctd\u003eSurgeon readiness and operating room adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and reimbursement authorities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e core access layers\u003c\/td\u003e\n\u003ctd\u003eFDA; NMPA; CE\/MDR\u003c\/td\u003e\n\u003ctd\u003eClearance, approval, and payment access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eItaly and Spain distribution partners\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e country markets\u003c\/td\u003e\n\u003ctd\u003eItaly; Spain\u003c\/td\u003e\n\u003ctd\u003eLocal sales, installation, and service coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe China structure is built around \u003cstrong\u003e1\u003c\/strong\u003e local joint venture with Fosun. The majority-owned structure matters because it gives the company a domestic operating platform for a market where device registration, procurement, and service support are tightly linked. A China partner is not just a sales channel; it is part of how the company handles local commercialization in a regulated market.\u003c\/p\u003e\n\n\u003cp\u003eHospitals and ambulatory surgery centers are the core customer base, split across \u003cstrong\u003e2\u003c\/strong\u003e care settings. In fiscal 2024, revenue was \u003cstrong\u003e$8.35 billion\u003c\/strong\u003e, up \u003cstrong\u003e17%\u003c\/strong\u003e, which shows how large the installed-base and recurring-revenue model has become. The partnership logic is simple: a facility buys capital equipment first, then generates repeat demand for instruments, accessories, and service as procedures continue.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e site types drive demand: hospitals and ambulatory surgery centers.\u003c\/li\u003e\n\u003cli\u003eRecurring revenue comes after the initial system placement.\u003c\/li\u003e\n\u003cli\u003eProcedure growth depends on how many teams keep the system in regular use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSurgeon training and education partners sit at \u003cstrong\u003e3\u003c\/strong\u003e adoption layers: simulation, proctoring, and credentialing. These partners matter because the system sale does not create value until surgeons and operating room staff are trained and approved to use it. Training support reduces the adoption barrier and helps turn a capital purchase into repeated procedure volume.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e practical steps shape adoption: simulation, proctoring, credentialing.\u003c\/li\u003e\n\u003cli\u003eAcademic medical centers and teaching hospitals are important training environments.\u003c\/li\u003e\n\u003cli\u003eClinical education shortens the time between purchase and steady use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegulatory and reimbursement access depends on \u003cstrong\u003e3\u003c\/strong\u003e major layers: FDA clearance in the US, NMPA oversight in China, and CE\/MDR access in Europe. Payment also depends on CMS and private payer decisions. If coverage is weak, hospitals can still buy equipment but may struggle with procedure economics; if coverage is broad, adoption can move faster.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e major access layers: FDA, NMPA, and CE\/MDR.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCMS\u003c\/strong\u003e and private payers shape payment economics.\u003c\/li\u003e\n\u003cli\u003eApproval and reimbursement work together, not separately.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eItaly and Spain are \u003cstrong\u003e2\u003c\/strong\u003e country distribution markets that rely on local partners rather than a single direct model. These partners support sales coverage, installation, and field service in each market. Local distribution matters because robotic surgery systems need more than shipment; they need on-site support and clinical coordination.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e European markets in this chapter: Italy and Spain.\u003c\/li\u003e\n\u003cli\u003eLocal partners support sales, installation, and service.\u003c\/li\u003e\n\u003cli\u003eCountry-level coverage helps maintain uptime and clinical continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eIn 2024, Intuitive Surgical, Inc. reported \u003cstrong\u003e$8.35 billion\u003c\/strong\u003e in revenue and \u003cstrong\u003e2.683 million\u003c\/strong\u003e da Vinci procedures, so its key activities are built around product development, industrial execution, surgeon enablement, regulatory work, and rollout discipline.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eReal-life data point\u003c\/th\u003e\n\u003cth\u003eBusiness meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotic system R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eda Vinci 5 cleared in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eStarts the next hardware and software refresh cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and supply chain management\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e revenue in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRequires reliable output of systems, instruments, accessories, and service parts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.683 million\u003c\/strong\u003e da Vinci procedures in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports recurring demand for instruments and accessories\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial momentum\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eShows adoption and utilization strength\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRobotic system R\u0026amp;D\u003c\/p\u003e\n\u003cp\u003eRobotic system R\u0026amp;D is the activity that keeps Intuitive Surgical, Inc. from standing still. The company's platform has to improve on visualization, instrumentation, software, ergonomics, and workflow because \u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures in \u003cstrong\u003e2024\u003c\/strong\u003e create a very large real-world test base. That scale matters: if a design change saves time in only a few minutes per case, the effect multiplies across millions of procedures. da Vinci 5 is central here because its 2024 clearance created a new upgrade cycle, and upgrade cycles matter in this business because they influence system placements, surgeon interest, and hospital spending.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures in \u003cstrong\u003e2024\u003c\/strong\u003e create constant product feedback.\u003c\/li\u003e\n\u003cli\u003eda Vinci 5 cleared in \u003cstrong\u003e2024\u003c\/strong\u003e and became part of the next cycle of upgrades and refinements.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D has to support both surgery platforms and broader clinical use cases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eManufacturing and supply chain management\u003c\/p\u003e\n\u003cp\u003eManufacturing is a core activity because Intuitive Surgical, Inc. sells capital systems and also recurring instruments, accessories, and service parts. That mix makes factory output and supply chain reliability directly tied to revenue, and 2024 revenue of \u003cstrong\u003e$8.35 billion\u003c\/strong\u003e shows the scale that the operations network has to support. In practical terms, the company has to make systems on schedule, keep parts available, and avoid disruptions that would delay hospital installations or procedure schedules. Supply chain work matters even more when the company is supporting both the installed base and new product rollout at the same time.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e revenue implies a large manufacturing and logistics footprint.\u003c\/li\u003e\n\u003cli\u003eSystem production has to align with installation dates and hospital readiness.\u003c\/li\u003e\n\u003cli\u003eInstrument and accessory supply has to stay available for repeated procedure use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSurgeon training and clinical education\u003c\/p\u003e\n\u003cp\u003eTraining is a commercial activity because hospitals do not buy robotic systems only on hardware specs. They also want proof that surgeons and staff can use the system safely and consistently. With \u003cstrong\u003e2.683 million\u003c\/strong\u003e da Vinci procedures in \u003cstrong\u003e2024\u003c\/strong\u003e, Intuitive Surgical, Inc. has to keep expanding clinical education so new users can move from first cases to regular use. Training is especially important when a hospital adopts a newer system like da Vinci 5, because the value of the system depends on actual case volume, not just installation. That is why education links directly to utilization and recurring consumable sales.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTraining supports the move from installation to regular procedure use.\u003c\/li\u003e\n\u003cli\u003eClinical education helps hospitals convert capital spending into case volume.\u003c\/li\u003e\n\u003cli\u003eNew platform adoption in \u003cstrong\u003e2024\u003c\/strong\u003e increased the need for user support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegulatory clearances and market expansion\u003c\/p\u003e\n\u003cp\u003eRegulatory work is one of the company's key activities because every new system, feature, and clinical use has to pass review before it can generate revenue at scale. da Vinci 5's \u003cstrong\u003e2024\u003c\/strong\u003e clearance is important because approval is the gate that opens commercialization. In this business, regulation is not just compliance work; it is a growth enabler. The company also has to keep expanding by market, hospital, and clinical indication, because robotic surgery and robotic-assisted lung biopsy both depend on country-level and use-case-level approval paths.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eda Vinci 5 clearance in \u003cstrong\u003e2024\u003c\/strong\u003e opened the next commercialization phase.\u003c\/li\u003e\n\u003cli\u003eApproval timing affects when hospitals can buy and use a system.\u003c\/li\u003e\n\u003cli\u003eMarket expansion depends on separate regulatory paths by country and application.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCommercial rollout of da Vinci 5 and Ion\u003c\/p\u003e\n\u003cp\u003eThe rollout of da Vinci 5 and Ion is the point where product development turns into revenue. da Vinci 5 needs installation, surgeon conversion, and steady use, while Ion needs adoption in lung biopsy workflows. The company's \u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in \u003cstrong\u003e2024\u003c\/strong\u003e shows why rollout execution matters: more cases mean more use of instruments, accessories, and service capacity. Late-\u003cstrong\u003e2025\u003c\/strong\u003e execution still depends on the same formula, with the installed base, meaning systems already in hospitals, needing ongoing support and the newer systems needing fast adoption.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eda Vinci 5 rollout depends on placement, training, and case utilization.\u003c\/li\u003e\n\u003cli\u003eIon rollout depends on adoption in lung biopsy and related clinical workflows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in \u003cstrong\u003e2024\u003c\/strong\u003e shows the commercial value of successful rollout.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical's key resources are its \u003cstrong\u003eda Vinci 5\u003c\/strong\u003e platform, its \u003cstrong\u003eIon\u003c\/strong\u003e endoluminal system, its \u003cstrong\u003e10,763\u003c\/strong\u003e-system installed base at December 31, 2024, its patent and software stack, and cash and investments above \u003cstrong\u003e$8 billion\u003c\/strong\u003e. These resources matter because they support \u003cstrong\u003e$8.35 billion\u003c\/strong\u003e of 2024 revenue and turn system placements into recurring sales of instruments, accessories, and service.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eda Vinci 5 platform\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe da Vinci 5 platform is the company's main capital asset and the center of its upgrade cycle. It received U.S. FDA clearance in \u003cstrong\u003e2024\u003c\/strong\u003e, which gave Intuitive Surgical a newer system to sell into hospitals that already use robotic surgery. That matters because a new platform can lift demand for replacements, upgrades, training, and service contracts. In the Business Model Canvas, this is a key resource because it keeps the installed base tied to Intuitive Surgical's ecosystem instead of a competitor's platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIon endoluminal system\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIon is Intuitive Surgical's second robotic platform and was FDA-cleared in \u003cstrong\u003e2019\u003c\/strong\u003e. It extends the company beyond abdominal and pelvic surgery into lung biopsy and bronchoscopy workflows. That widens the addressable market and reduces reliance on one procedure family. As a key resource, Ion gives Intuitive Surgical a second clinical entry point, a second set of customers, and another source of recurring instrument and service revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal installed base\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe installed base is one of Intuitive Surgical's strongest resources because it creates recurring demand after the original system sale. At December 31, 2024, the company reported \u003cstrong\u003e10,763\u003c\/strong\u003e da Vinci systems installed worldwide. In 2024, da Vinci procedures reached \u003cstrong\u003e2.68 million\u003c\/strong\u003e. That scale matters because more procedures mean more use of disposable and limited-use instruments, more service work, and more reason for hospitals to stay inside the Intuitive Surgical platform.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eda Vinci 5 platform\u003c\/td\u003e\n\u003ctd\u003eFDA clearance in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports system upgrades and replacement demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIon endoluminal system\u003c\/td\u003e\n\u003ctd\u003eFDA clearance in \u003cstrong\u003e2019\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpands the company into robotic bronchoscopy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal installed base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10,763\u003c\/strong\u003e da Vinci systems at December 31, 2024\u003c\/td\u003e\n\u003ctd\u003eDrives recurring instruments, accessories, and service revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure volume\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.68 million\u003c\/strong\u003e da Vinci procedures in 2024\u003c\/td\u003e\n\u003ctd\u003eShows utilization depth and platform stickiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue scale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e in 2024 revenue\u003c\/td\u003e\n\u003ctd\u003eShows the size of the resource base in commercial terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and investment reserves\u003c\/td\u003e\n\u003ctd\u003eAbove \u003cstrong\u003e$8 billion\u003c\/strong\u003e at year-end 2024\u003c\/td\u003e\n\u003ctd\u003eFunds R\u0026amp;D, manufacturing, and expansion without debt dependence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntellectual property and AI tools\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIntuitive Surgical's intellectual property is a core defense against copycats. Its patent portfolio, software, image processing, data capture, and machine-assisted features support system performance and product differentiation. AI tools matter because robotic surgery depends on sensing, visualization, workflow software, and continuous system improvement. In simple terms, the software layer protects the hardware business by making the platform harder to copy and easier to upgrade. That helps preserve pricing power and supports long product life cycles.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e10,763\u003c\/strong\u003e da Vinci systems formed the global installed base at December 31, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.68 million\u003c\/strong\u003e da Vinci procedures were performed in 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e in 2024 revenue shows the scale of monetization from these resources.\u003c\/li\u003e\n\u003cli\u003eda Vinci 5 was FDA-cleared in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIon was FDA-cleared in \u003cstrong\u003e2019\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and investments were above \u003cstrong\u003e$8 billion\u003c\/strong\u003e at year-end 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLarge cash and investment reserves\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLarge cash and investment reserves are a strategic resource because they give Intuitive Surgical room to spend on research, manufacturing capacity, clinical development, and commercial expansion without relying on debt markets. That matters in robotics, where product cycles are long and upfront spending is heavy. Cash also gives the company flexibility to handle slower hospital purchasing periods, supply chain costs, and new platform launches while still funding future products.\u003c\/p\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical, Inc.'s value proposition is anchored by \u003cstrong\u003e8,606\u003c\/strong\u003e installed systems, \u003cstrong\u003e1,526\u003c\/strong\u003e system placements in 2023, more than \u003cstrong\u003e2.2 million\u003c\/strong\u003e procedures in 2023, and \u003cstrong\u003e$7.12 billion\u003c\/strong\u003e in 2023 revenue. The model links system sales to repeat demand for instruments, accessories, and service.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue proposition\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eData point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimally invasive robotic surgery\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,606\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInstalled systems at December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimally invasive robotic surgery\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,526\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSystem placements in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimally invasive robotic surgery\u003c\/td\u003e\n\u003ctd\u003emore than \u003cstrong\u003e2.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eProcedures in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring instruments, accessories, and service\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLower per-procedure cost via 15-use instruments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUses per selected newer instrument\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-driven intraoperative performance insights\u003c\/td\u003e\n\u003ctd\u003emore than \u003cstrong\u003e10,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTimes the computing power of the newer platform versus the prior generation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpanded procedure access and clinical precision\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMajor specialty areas: general surgery, urology, gynecology, thoracic surgery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMinimally invasive robotic surgery\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe core clinical value proposition rests on \u003cstrong\u003e8,606\u003c\/strong\u003e installed systems and more than \u003cstrong\u003e2.2 million\u003c\/strong\u003e procedures in 2023. The scale of \u003cstrong\u003e1,526\u003c\/strong\u003e system placements in 2023 shows that the platform keeps expanding across hospitals and surgical centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e installed systems\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,526\u003c\/strong\u003e system placements in 2023\u003c\/li\u003e\n\u003cli\u003emore than \u003cstrong\u003e2.2 million\u003c\/strong\u003e procedures in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring instruments, accessories, and service\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe commercial value proposition is not a one-time hardware sale. Intuitive Surgical, Inc. reported \u003cstrong\u003e$7.12 billion\u003c\/strong\u003e in 2023 revenue, and the installed base of \u003cstrong\u003e8,606\u003c\/strong\u003e systems creates repeated demand for instruments, accessories, and service.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e systems at year-end 2023\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,526\u003c\/strong\u003e systems placed in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLower per-procedure cost via 15-use instruments\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSelected newer instruments support up to \u003cstrong\u003e15\u003c\/strong\u003e uses. That number matters because the same instrument can be spread across \u003cstrong\u003e15\u003c\/strong\u003e procedures instead of a single case use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e uses per selected newer instrument\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e procedures per instrument life cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI-driven intraoperative performance insights\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe newer platform is described as having more than \u003cstrong\u003e10,000\u003c\/strong\u003e times the computing power of the prior generation. That scale supports more data capture and more software-based performance feedback during surgery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003emore than \u003cstrong\u003e10,000\u003c\/strong\u003e times computing power\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e newer platform generation with higher onboard processing capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpanded procedure access and clinical precision\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform spans \u003cstrong\u003e4\u003c\/strong\u003e major specialty areas: general surgery, urology, gynecology, and thoracic surgery. Combined with \u003cstrong\u003e8,606\u003c\/strong\u003e installed systems and more than \u003cstrong\u003e2.2 million\u003c\/strong\u003e annual procedures, the value proposition is broader procedure access with repeatable surgical precision.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major specialty areas\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e installed systems\u003c\/li\u003e\n\u003cli\u003emore than \u003cstrong\u003e2.2 million\u003c\/strong\u003e procedures in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical, Inc. builds customer relationships around \u003cstrong\u003e8,606\u003c\/strong\u003e installed systems and \u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures in 2023. The relationship is recurring, service-heavy, and training-intensive rather than a one-time equipment sale.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer relationship element\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eBusiness model effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term service contracts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e installed systems; \u003cstrong\u003e$7.12 billion\u003c\/strong\u003e total revenue in 2023\u003c\/td\u003e\n\u003ctd\u003ePost-sale contact continues across the installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOngoing surgeon training\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures in 2023; about \u003cstrong\u003e22%\u003c\/strong\u003e year-over-year growth\u003c\/td\u003e\n\u003ctd\u003eHigher case volume increases repeat training needs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDedicated commercial and clinical support\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e265.7\u003c\/strong\u003e procedures per installed system in 2023\u003c\/td\u003e\n\u003ctd\u003eField support stays tied to active usage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeasured product onboarding\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures across \u003cstrong\u003e8,606\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003eAdoption can be tracked after installation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerformance data and workflow support\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures\u003c\/td\u003e\n\u003ctd\u003eLarge-case-volume data supports workflow feedback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eLong-term service contracts sit on top of the installed base. With \u003cstrong\u003e8,606\u003c\/strong\u003e systems in place at the end of 2023, Intuitive Surgical, Inc. had a large base of customers that needed continued service, maintenance, and account management after the original sale. The company reported \u003cstrong\u003e$7.12 billion\u003c\/strong\u003e in total revenue in 2023, which shows that the customer relationship is not limited to upfront equipment revenue.\u003c\/p\u003e\n\n\u003cp\u003eOngoing surgeon training is tied to procedure volume. Intuitive Surgical, Inc. reported \u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures in 2023, up about \u003cstrong\u003e22%\u003c\/strong\u003e from 2022. That scale matters because every additional procedure expands the number of surgeons, operating room staff, and hospital teams that need repeated training and procedural familiarity.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures in 2023 created the training base.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e22%\u003c\/strong\u003e year-over-year procedure growth increased training demand.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e installed systems expanded the number of sites needing education support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDedicated commercial and clinical support is easier to justify when usage is high. Dividing \u003cstrong\u003e2,286,000\u003c\/strong\u003e procedures by \u003cstrong\u003e8,606\u003c\/strong\u003e installed systems gives about \u003cstrong\u003e265.7\u003c\/strong\u003e procedures per system in 2023. That ratio shows why field teams, application specialists, and clinical support staff remain important after installation.\u003c\/p\u003e\n\n\u003cp\u003eMeasured product onboarding is visible in the gap between the installed base and procedure volume. Intuitive Surgical, Inc. did not just place \u003cstrong\u003e8,606\u003c\/strong\u003e systems; it also supported \u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures in the same year. That means onboarding is tracked through utilization, not only through shipment of equipment.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e8,606\u003c\/strong\u003e systems created the onboarding base.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures show whether the onboarding translated into use.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e265.7\u003c\/strong\u003e procedures per system provides a utilization benchmark.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePerformance data and workflow support are central to retention because the company can learn from \u003cstrong\u003e2.286 million\u003c\/strong\u003e procedures. That volume gives Intuitive Surgical, Inc. enough operating data to support workflow reviews, utilization tracking, and site-level performance discussions across a very large clinical base.\u003c\/p\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eIn \u003cstrong\u003e2024\u003c\/strong\u003e, Intuitive Surgical reported \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e in revenue and \u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures, so its channel mix is built around system sales, recurring use, and surgeon adoption rather than one-time transactions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life data\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales to hospitals and ambulatory surgery centers\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e$8.352 billion\u003c\/strong\u003e revenue in 2024\u003c\/td\u003e\n \u003ctd\u003eCapital system selling, account expansion, and recurring use\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal commercial teams\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures in 2024\u003c\/td\u003e\n \u003ctd\u003eCoverage, selling, and adoption support across markets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional distribution operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e global revenue base of \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eDelivery, installation support, and supply flow\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon training programs\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures in 2024\u003c\/td\u003e\n \u003ctd\u003eLearning, credentialing, and utilization growth\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct and clinical launch events\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e revenue of \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eDemonstration, evaluation, and adoption of new products\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect sales to hospitals and ambulatory surgery centers\u003c\/strong\u003e are the main buying channel. This is the point where Intuitive Surgical sells capital systems, installs them in operating rooms, and turns each placement into future instrument, accessory, and service demand. The \u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures performed in \u003cstrong\u003e2024\u003c\/strong\u003e show why the channel matters: hospitals and ASCs do not just buy a machine, they buy a workflow that must keep running case after case.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercial teams\u003c\/strong\u003e are the field engine behind that model. Their job is account coverage, procedure growth, and long-cycle sales support in each market. The commercial channel matters because a surgical platform becomes more valuable when usage rises, and Intuitive Surgical's \u003cstrong\u003e2024\u003c\/strong\u003e procedure volume of \u003cstrong\u003e2.683 million\u003c\/strong\u003e is the clearest sign of scale. In academic writing, you can link this channel to enterprise selling, where one sale can lead to years of follow-on revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegional distribution operations\u003c\/strong\u003e keep the channel working after the sale. These operations move systems, parts, instruments, and service support across markets, which is essential for a company with \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e revenue. For a business model canvas, this channel is important because it connects physical delivery to installed-base support. Without regional logistics, system placement, replacement parts, and ongoing supply would slow down.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSurgeon training programs\u003c\/strong\u003e are a channel because adoption depends on people, not just equipment. Intuitive Surgical has to train surgeons, operating room teams, and hospital staff so that the system gets used at a high enough rate to justify the purchase. The relevance of training shows up in the \u003cstrong\u003e2.683 million\u003c\/strong\u003e procedures recorded in \u003cstrong\u003e2024\u003c\/strong\u003e. In plain English, the more trained users a hospital has, the more likely the system is to be used often enough to support recurring revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduct and clinical launch events\u003c\/strong\u003e are the formal channel for introducing new systems, instruments, and clinical workflows to customers. These events matter because surgical adoption often requires demonstrations, peer learning, and clinical evidence before a hospital commits capital. Intuitive Surgical's \u003cstrong\u003e2024\u003c\/strong\u003e revenue of \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e shows that launch activity sits inside a much larger commercial engine, not as a separate business line.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals and ASCs are the first purchase point for capital systems.\u003c\/li\u003e\n \u003cli\u003eCommercial teams support account development across the entire installed base.\u003c\/li\u003e\n \u003cli\u003eDistribution operations support delivery, installation, and supply continuity.\u003c\/li\u003e\n \u003cli\u003eTraining programs support adoption and higher procedure volumes.\u003c\/li\u003e\n \u003cli\u003eLaunch events support system introduction and clinical acceptance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical, Inc. sells into hospitals and ambulatory surgery centers, while surgeons and surgical teams drive how often the systems are used. In 2024, the company reported \u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures and \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e in revenue, so utilization is the main economic driver.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eBuyer role\u003c\/th\u003e\n\u003cth\u003eReal-life data point\u003c\/th\u003e\n\u003cth\u003eBusiness model effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eCapital buyer\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures in 2024\u003c\/td\u003e\n \u003ctd\u003eDrives system placement, recurring instruments, and service revenue\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory surgery centers\u003c\/td\u003e\n\u003ctd\u003eGrowth site buyer\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in 2024\u003c\/td\u003e\n \u003ctd\u003eExpands use beyond inpatient hospital settings\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeons and surgical teams\u003c\/td\u003e\n\u003ctd\u003eClinical decision makers\u003c\/td\u003e\n\u003ctd\u003eRevenue per procedure of about \u003cstrong\u003e$3,112\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eDetermines case volume per installed system\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrology, gynecology, and general surgery providers\u003c\/td\u003e\n \u003ctd\u003eCore specialty users\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures in 2024\u003c\/td\u003e\n \u003ctd\u003eAnchors recurring utilization and repeat purchases\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac procedure centers and international markets\u003c\/td\u003e\n \u003ctd\u003eSelective and geographic buyers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in 2024; \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e revenue\u003c\/td\u003e\n \u003ctd\u003eAdds growth outside mature U.S. programs\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals\u003c\/strong\u003e are the main economic buyer. They approve capital spending, decide where robotic programs sit inside operating rooms, and set the case mix that determines system use. That matters because the company's revenue depends on repeated procedures, not just system placement. The 2024 procedure total of \u003cstrong\u003e2,683,000\u003c\/strong\u003e shows the scale of hospital-led demand.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHospitals buy the system and fund the operating room workflow.\u003c\/li\u003e\n \u003cli\u003eHospitals capture inpatient, high-acuity, and multi-specialty cases.\u003c\/li\u003e\n \u003cli\u003eHospitals matter because each additional procedure supports recurring instruments and service revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAmbulatory surgery centers\u003c\/strong\u003e are the outpatient growth segment. They matter because same-day surgery shifts cases away from inpatient settings and puts pressure on throughput, scheduling, and operating room efficiency. The company's \u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in 2024 shows that demand is not limited to large hospitals.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eASCs focus on outpatient procedures and faster patient turnover.\u003c\/li\u003e\n \u003cli\u003eASCs are important where payers and providers want lower site-of-care costs.\u003c\/li\u003e\n \u003cli\u003eASCs expand the addressable market beyond traditional hospital systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSurgeons and surgical teams\u003c\/strong\u003e are the adoption gatekeepers. They decide whether a procedure uses robotic assistance, and their training depth affects how many cases a system can support. The company's 2024 revenue of \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e and calculated revenue per procedure of about \u003cstrong\u003e$3,112\u003c\/strong\u003e show why utilization matters more than unit sales alone.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSurgeons choose the technique for each case.\u003c\/li\u003e\n \u003cli\u003eSurgical teams affect setup time, turnover time, and training consistency.\u003c\/li\u003e\n \u003cli\u003eHigher surgeon adoption increases procedure volume per installed system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eUrology, gynecology, and general surgery providers\u003c\/strong\u003e form the core specialty base. These are the high-frequency procedure areas that support repeat use and recurring product consumption. With \u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures in 2024, these specialties sit at the center of the company's customer mix.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eUrology programs are a major source of recurring surgical volume.\u003c\/li\u003e\n \u003cli\u003eGynecology programs add elective and semi-elective cases.\u003c\/li\u003e\n \u003cli\u003eGeneral surgery broadens the procedure base across hospitals and ASCs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiac procedure centers and international markets\u003c\/strong\u003e are more selective but important for long-term expansion. Cardiac programs need specialized clinical capability, while international markets depend on local reimbursement, regulation, and hospital budgets. The company's \u003cstrong\u003e17%\u003c\/strong\u003e procedure growth in 2024 shows that this customer base is still widening across geographies.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCardiac centers require specialized teams and specialized case selection.\u003c\/li\u003e\n \u003cli\u003eInternational markets add growth outside the largest U.S. hospital accounts.\u003c\/li\u003e\n \u003cli\u003eCross-border adoption depends on approvals, reimbursement, and training capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$7.12B\u003c\/strong\u003e revenue, \u003cstrong\u003e$2.41B\u003c\/strong\u003e cost of revenue, \u003cstrong\u003e$1.11B\u003c\/strong\u003e R\u0026amp;D, and \u003cstrong\u003e$1.78B\u003c\/strong\u003e SG\u0026amp;A in 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003e2023 line item\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003e% of revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$7.12B\u003c\/td\u003e\n\u003ctd\u003e100.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of revenue\u003c\/td\u003e\n\u003ctd\u003e$2.41B\u003c\/td\u003e\n\u003ctd\u003e33.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross profit\u003c\/td\u003e\n\u003ctd\u003e$4.71B\u003c\/td\u003e\n\u003ctd\u003e66.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e$1.11B\u003c\/td\u003e\n\u003ctd\u003e15.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e$1.78B\u003c\/td\u003e\n\u003ctd\u003e25.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and product development\u003c\/strong\u003e: \u003cstrong\u003e$1.11B\u003c\/strong\u003e in 2023, or \u003cstrong\u003e15.6%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$1.11B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e15.6%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$7.12B\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and supply chain costs\u003c\/strong\u003e: \u003cstrong\u003e$2.41B\u003c\/strong\u003e in cost of revenue in 2023, or \u003cstrong\u003e33.8%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$2.41B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e33.8%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$4.71B\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCommercial and marketing expenses\u003c\/strong\u003e: \u003cstrong\u003e$1.78B\u003c\/strong\u003e in SG\u0026amp;A in 2023, or \u003cstrong\u003e25.0%\u003c\/strong\u003e of revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$1.78B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e25.0%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$7.12B\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTraining and clinical support costs\u003c\/strong\u003e: not separately disclosed.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2023 disclosure\u003c\/th\u003e\n\u003cth\u003eRelated cost bucket\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining and clinical support\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eSG\u0026amp;A and cost of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff impact\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eCost of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational expansion\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eSG\u0026amp;A and R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eTariff and international expansion costs\u003c\/strong\u003e: not separately disclosed; embedded in the \u003cstrong\u003e$2.41B\u003c\/strong\u003e cost of revenue base and the \u003cstrong\u003e$1.78B\u003c\/strong\u003e SG\u0026amp;A base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$2.41B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$1.78B\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003eNot separately disclosed\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$8.352 billion\u003c\/strong\u003e in 2024 revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$3,113\u003c\/strong\u003e average revenue per procedure in 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.352 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 procedures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,683,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue per procedure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,113\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRobotic system sales\u003c\/strong\u003e: \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstruments and accessories\u003c\/strong\u003e: \u003cstrong\u003e2,683,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eService contracts\u003c\/strong\u003e: \u003cstrong\u003e$3,113\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProcedure-driven recurring revenue\u003c\/strong\u003e: \u003cstrong\u003e$8.352 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEndoluminal system sales and utilization\u003c\/strong\u003e: \u003cstrong\u003e2,683,000\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601605062805,"sku":"isrg-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/isrg-business-model-canvas.png?v=1740185873","url":"https:\/\/dcf-analysis.com\/products\/isrg-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}